

Curriculum vitae

Dr. Heikki Lanckriet

Profession: CEO of 4basebio PLC, Cambridge, United Kingdom

Nationality: Belgian

Place of birth: Ypern

Date of birth: *1977

Professional career:

2019 - today	CEO 4basebio PLC
2016 – 2019	CEO Sygnis AG / Expedeon AG
2008 – 2016	CEO Expedeno Group
2005 – 2008	COO Novexin
2002 – 2005	Co-founder & CSO Novexin

Education:

2001 - 2004	Ph.D. in Chemical Engineering, University of Cambridge
1995 - 2000	Master of Engineering (M.Eng.) in Chemical Engineering, Ghent University (Belgium)

Membership of other statutory supervisory boards and comparable domestic and foreign supervisory bodies of commercial enterprises:

- Neophore Ltd, Cambridge, United Kingdom, Non-Executive Director
- I2i Capital Ltd, Cambridge, United Kingdom, Member of the Board of Directors
- Kither Biotech S.R.L., Turin, Italy, Non-Executive Board Member
- Leucid Bio, London, United Kingdom, Non-Executive Director
- Neomatrix S.R.L., Rome, Italy, Non-Executive Director
- Biofrontera Inc., Woburn, Massachusetts, United States, Non-Executive Director

The group of companies led by Wilhelm K. T. Zours, to whom 62.23% of the voting rights in Biofrontera AG are attributed according to the most recent voting rights notification, holds a 32.95% stake in 4basebio PLC, of which Dr. Heikki Lanckriet is a member of the Executive Board. Consequently, there is a business relationship between Dr. Heikki Lanckriet and a shareholder with a significant stake in the company.